Targeted drug therapies have been developed to address the altered cell growth mechanisms in NSCLC.1 The treatment of advanced-stage NSCLC relies on immunotherapeutic drugs, particularly tyrosine kinase inhibitors (TKIs), which target specific mutations in the epidermal growth factor receptor (EGFR) gene. This evidence concerns the gene EGFR and non-small cell lung carcinoma.